MED
The numbers are in, and they’re... fine
Medifast just dropped its first-quarter 2026 results, and the headline is basically: not great, not terrible. Revenue came in at $76.0 million, the company posted a net loss of $2.1 million, and diluted EPS landed at a loss of $0.19.
That’s the kind of report that doesn’t exactly throw confetti, but it does give you a few things to watch. The company ended the quarter with $168.9 million in cash, cash equivalents, and investment securities, and it still carries no debt. In a shaky consumer backdrop, that balance sheet matters more than the average “we’re optimistic” paragraph.
The coach business is still doing the heavy lifting
Medifast said it had 14,000 independent active earning coaches and revenue per active earning coach of $5,432. That’s the engine here: if the coach network stabilizes and starts pulling more customers back in, the revenue story gets better fast. If it doesn’t, well, the treadmill keeps spinning.
For investors, the key question is whether this is the early outline of a turnaround or just a company proving it can lose less money while still waiting for demand to re-appear. The cash pile buys time. It doesn’t buy growth.
Why you should care
This was an earnings report, not a fireworks show. But in a name like Medifast, the market is usually looking for any sign that the core business is getting its groove back. If revenues can start moving the right way, the stock gets a cleaner narrative. If not, this may stay in “show me” mode for a while.
Big picture: the company isn’t in crisis, but it also isn’t back on offense yet.